Biblio

9 resultats trouvés
Filtres: Auteur is Mejean, Arnaud  [Clear All Filters]
A
Roumiguie M, Paoletti X, Neuzillet Y, Mathieu R, Vincendeau S, Kleinclauss F, Mejean A, Guy L, Timsit MOlivier, Lebret T.  2021.  Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis. FUTURE ONCOLOGY. 17:1811-1823.
Roumiguie M, Paoletti X, Neuzillet Y, Mathieu R, Vincendeau S, Kleinclauss F, Mejean A, Guy L, Timsit MOlivier, Lebret T.  Submitted.  Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis. FUTURE ONCOLOGY.
C
Mejean A, Escudier B, Thezenas S, Beauval J-B, Geoffroy L, Bensalah K, Thiery-Vuillemin A, Cormier L, Lang H, Guy L et al..  2018.  CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma-Results of a phase III noninferiority trial.. JOURNAL OF CLINICAL ONCOLOGY. 36
Mejean A, Thezenas S, Chevreau C, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G et al..  2019.  Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.. JOURNAL OF CLINICAL ONCOLOGY. 37
L
Bigot P, Bernhard J-C, Flamand V, Gill I, Verhoest G, Beauval JBaptiste, Nouhaud FXavier, Suer E, Ploussard G, Francois J et al..  2017.  Localized chromophobe carcinomas treated by nephron-spanng surgery have excellent oncologic outcomes. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 35
Da Silva A, Flechon A, Culine S, Coquan E, Vuillemin AThiery, Planchamp F, Murez T, Mejean A, Pasquier D, Fizazi K et al..  2021.  Localized testicular germ cell tumor (TGCT) surveillance: A Delphi consensus study.. JOURNAL OF CLINICAL ONCOLOGY. 39
N
Lang H, Mouracade P, Gimel P, Bernhard JC, Pignot G, Zini L, Crepel M, Rigaud J, Salomon L, Bellec L et al..  2014.  National prospective study on the use of local haemostatic agents during partial nephrectomy. BJU INTERNATIONAL. 113:E56-E61.
S
Mejean A, Ravaud A, Thezenas S, Chevreau C, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L et al..  2021.  Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy? EUROPEAN UROLOGY. 80:417-424.
T
Bigot P, Bernhard J-C, Gill IS, Vuong NSon, Verhoest G, Flamand V, Reix B, Suer E, Gokce I, Beauval JBaptiste et al..  2016.  The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery. WORLD JOURNAL OF UROLOGY. 34:347-352.